Literature DB >> 2522748

In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine.

D R Cook1, R L Stiller, J N Weakly, S Chakravorti, B W Brandom, R M Welch.   

Abstract

The in vitro rates of metabolism of mivacurium chloride and succinylcholine in pooled human plasma were compared. In addition, the rate of metabolism of mivacurium in buffered solutions of butyrylcholinesterase (E.C. 3.1.1.8) and acetylcholinesterase (E.C. 3.1.1.7) was determined. Succinylcholine concentrations were measured spectrophotometrically, and mivacurium concentrations were determined with a high-pressure liquid chromatographic assay. The hydrolysis of mivacurium in plasma followed first-order kinetics, and the rate of hydrolysis decreased as plasma was serially diluted. The Michaelis-Menten constant (Km) for mivacurium metabolism in plasma was 245 mumol/L, and the maximum velocity (Vmax) was 50 U/L; the Km for succinylcholine was 37 mumol/L, and Vmax was 74 U/L. At comparable multiples of the Km the hydrolysis rate of mivacurium was 70% of that of succinylcholine. Mivacurium was metabolized significantly in solutions containing butyrylcholinesterase, but only minimally in solutions containing acetylcholinesterase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522748

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  11 in total

Review 1.  [Esters and stereoisomers].

Authors:  V Nigrovic; C Diefenbach; H Mellinghoff
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 2.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

3.  Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

Authors:  R G Stout; S J Brull; D Kelly; D G Silverman
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 4.  Natural inhibitors of cholinesterases: implications for adverse drug reactions.

Authors:  M D Krasowski; D S McGehee; J Moss
Journal:  Can J Anaesth       Date:  1997-05       Impact factor: 5.063

5.  Dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block during N2O-enflurane-alfentanil anaesthesia.

Authors:  J Marcotte; P Drolet; L Perreault; M Girard
Journal:  Can J Anaesth       Date:  1995-10       Impact factor: 5.063

Review 6.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 7.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Surgeon-controlled mivacurium administration during elective caesarean section.

Authors:  M Abdulatif; E Taylouni
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

10.  Edrophonium requirements for reversal of deep neuromuscular block following infusion of mivacurium.

Authors:  D R Miller; G Bryson; R J Martineau; J B Kitts; M Curran; P Bragg; J B Watson; K Hull; P Lindsay
Journal:  Can J Anaesth       Date:  1995-11       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.